As a nonpeptide thrombopoietin receptor (TpoR) agonist, Eltrombopag has been used in clinical settings to treat primary immunologic thrombocytopenic purpura (ITP)[60, 61] and severe aplastic anemia (AA).[62] In MM, thrombocytopenia is a common complication that leads to poor prognosis.[63] Treatment with TPO can suppress MM progression,[63] suggesting that Eltrombopag may be a potential drug for MM. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.